KR20130054955A - 내생적으로 태그된 단백질을 생성하기 위한 방법 - Google Patents

내생적으로 태그된 단백질을 생성하기 위한 방법 Download PDF

Info

Publication number
KR20130054955A
KR20130054955A KR1020127028946A KR20127028946A KR20130054955A KR 20130054955 A KR20130054955 A KR 20130054955A KR 1020127028946 A KR1020127028946 A KR 1020127028946A KR 20127028946 A KR20127028946 A KR 20127028946A KR 20130054955 A KR20130054955 A KR 20130054955A
Authority
KR
South Korea
Prior art keywords
sequence
cell
protein
cells
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127028946A
Other languages
English (en)
Korean (ko)
Inventor
드미트리 말코브
나탄 젠서
데보라 바사르
팬 장
홍이 장
Original Assignee
시그마-알드리치 컴퍼니., 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그마-알드리치 컴퍼니., 엘엘씨 filed Critical 시그마-알드리치 컴퍼니., 엘엘씨
Publication of KR20130054955A publication Critical patent/KR20130054955A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/72—Fusion polypeptide containing domain for protein-protein interaction containing SH2 domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020127028946A 2010-04-13 2011-04-13 내생적으로 태그된 단백질을 생성하기 위한 방법 Ceased KR20130054955A (ko)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US32369810P 2010-04-13 2010-04-13
US32371910P 2010-04-13 2010-04-13
US32370210P 2010-04-13 2010-04-13
US61/323,719 2010-04-13
US61/323,702 2010-04-13
US61/323,698 2010-04-13
US36701710P 2010-07-23 2010-07-23
US61/367,017 2010-07-23
US39066810P 2010-10-07 2010-10-07
US61/390,668 2010-10-07
US40885610P 2010-11-01 2010-11-01
US61/408,856 2010-11-01
US201161431957P 2011-01-12 2011-01-12
US61/431,957 2011-01-12
PCT/US2011/032218 WO2011130346A1 (en) 2010-04-13 2011-04-13 Methods for generating endogenously tagged protein

Publications (1)

Publication Number Publication Date
KR20130054955A true KR20130054955A (ko) 2013-05-27

Family

ID=44799004

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127028946A Ceased KR20130054955A (ko) 2010-04-13 2011-04-13 내생적으로 태그된 단백질을 생성하기 위한 방법
KR1020127028401A Ceased KR20130055588A (ko) 2010-04-13 2011-04-13 이형 단백질을 발현시키기 위한 내생 프로모터의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020127028401A Ceased KR20130055588A (ko) 2010-04-13 2011-04-13 이형 단백질을 발현시키기 위한 내생 프로모터의 용도

Country Status (10)

Country Link
US (5) US20130065310A1 (https=)
EP (2) EP2558574B1 (https=)
JP (2) JP5841996B2 (https=)
KR (2) KR20130054955A (https=)
CN (3) CN102959078B (https=)
BR (1) BR112012026379A2 (https=)
CA (2) CA2795636C (https=)
DK (1) DK2558575T3 (https=)
ES (1) ES2565216T3 (https=)
WO (3) WO2011130343A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512444B2 (en) 2010-07-23 2016-12-06 Sigma-Aldrich Co. Llc Genome editing using targeting endonucleases and single-stranded nucleic acids
US9012617B2 (en) * 2011-04-11 2015-04-21 The Trustees Of The University Of Pennsylvania Detection reagents for tyrosine kinase activity and methods of use thereof
AU2012347919B2 (en) * 2011-12-05 2017-02-02 Factor Bioscience Inc. Methods and products for transfecting cells
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
CA2868575C (en) 2012-03-27 2022-11-01 The University Of Western Ontario Sh2 domain variants
EP2839013B1 (en) * 2012-04-18 2020-08-26 The Board of Trustees of the Leland Stanford Junior University Non-disruptive gene targeting
AU2013335451C1 (en) 2012-10-23 2024-07-04 Toolgen Incorporated Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
RU2662932C2 (ru) 2013-03-14 2018-07-31 Карибо Биосайенсиз, Инк. Композиции и способы с участием нуклеиновых кислот, нацеленных на нуклеиновые кислоты
BR112016019940A2 (pt) 2014-03-21 2017-10-24 Univ Leland Stanford Junior edição de genoma sem nucleases
PT3514172T (pt) * 2014-04-01 2020-04-21 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Imunorrecetores específicos de claudina-6 e epítopos de células t
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
EP4464338A3 (en) 2014-11-07 2025-02-12 Editas Medicine, Inc. Systems for improving crispr/cas-mediated genome-editing
US11440946B2 (en) 2015-03-13 2022-09-13 University Of Maryland, Baltimore Universal antibody-mediated biosensor
EP3353296B1 (en) 2015-09-24 2020-11-04 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
KR20250141836A (ko) * 2015-11-04 2025-09-29 페이트 세러퓨틱스, 인코포레이티드 만능 세포의 유전자 조작
WO2017109292A1 (en) * 2015-12-23 2017-06-29 Teknologian Tutkimuskeskus Vtt Oy A method for obtaining indicator signals from a cell
US11597924B2 (en) 2016-03-25 2023-03-07 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
US11236313B2 (en) 2016-04-13 2022-02-01 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
CN106800602B (zh) * 2017-01-22 2020-05-01 中国科学院生物物理研究所 一种可视化标记基因组位点的方法
WO2018148603A1 (en) * 2017-02-09 2018-08-16 Allen Institute Genetically-tagged stem cell lines and methods of use
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
WO2019118879A1 (en) * 2017-12-14 2019-06-20 Donald Danforth Plant Science Center Homologous recombination via transcriptional activation
EP3788150A4 (en) * 2018-05-04 2022-01-26 Sigma-Aldrich Co. LLC PRODUCTION OF RECOMBINANT PROTEINS WITH REDUCED LEVELS OF HOST CELL PROTEINS
WO2020084034A1 (en) 2018-10-26 2020-04-30 F. Hoffmann-La Roche Ag Multispecific antibody screening method using recombinase mediated cassette exchange
EP3902915B1 (en) * 2018-12-30 2023-08-23 F. Hoffmann-La Roche AG Method for the selection of cells based on crispr/cas-controlled integration of a detectable tag to a target protein
EP4031583A4 (en) * 2019-09-16 2023-11-15 Fred Hutchinson Cancer Center CHIMERIC RECEPTOR PROTEINS AND THEIR USES
CN113684228B (zh) * 2021-10-26 2022-03-11 天九再生医学(天津)科技有限公司 利用内参快速准确表征蛋白质相对丰度的方法
CN114703174B (zh) * 2022-04-12 2023-10-24 中国科学院海洋研究所 快速获得基因型和表型突变的CRISPR/Cas9基因敲除方法及应用
CN115948401A (zh) * 2022-12-19 2023-04-11 中国科学技术大学 一种多靶点rna靶向敲低系统及应用
CN120177781B (zh) * 2025-05-22 2025-08-12 南京师范大学 生物传感器及其应用和高通量筛选花姜酮生产菌的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192772B1 (en) * 1988-08-31 2007-03-20 The University Of Florida Research Foundations, Inc. Recombinant cells that highly express chromosomally-integrated heterologous gene
US7090976B2 (en) * 1999-11-10 2006-08-15 Rigel Pharmaceuticals, Inc. Methods and compositions comprising Renilla GFP
US6495664B1 (en) * 1998-07-24 2002-12-17 Aurora Biosciences Corporation Fluorescent protein sensors of post-translational modifications
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6710170B2 (en) * 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US7125660B2 (en) * 2000-09-13 2006-10-24 Archemix Corp. Nucleic acid sensor molecules and methods of using same
AU2002327730A1 (en) * 2001-09-26 2003-04-07 University Of North Carolina At Chapel Hill Variants of alpha-fetoprotein coding and expression sequences
AU2004263865B2 (en) * 2003-08-08 2007-05-17 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
US7402436B2 (en) * 2004-05-03 2008-07-22 City Of Hope Lentiviral vectors for site-specific gene insertion
WO2006017751A2 (en) * 2004-08-02 2006-02-16 Cellumen, Inc. Methods for the detection of molecular interactions within cells
AU2005287278B2 (en) * 2004-09-16 2011-08-04 Sangamo Biosciences, Inc. Compositions and methods for protein production
US20060171929A1 (en) * 2005-01-31 2006-08-03 The University Of Washington Regulation of dendritic cell functions by the DCAL-2 receptor
EP1869206A4 (en) * 2005-03-02 2011-08-10 Einstein Coll Med ENZYME SENSORS WITH ENVIRONMENTAL SENSITIVE OR FLUORESCENT LABELS AND APPLICATIONS THEREOF
WO2006094073A2 (en) * 2005-03-02 2006-09-08 Acadia Pharmaceuticals Inc. Functional bioluminescence energy resonance transfer (bret) assay to screen, identify and characterize receptor tyrosine kinase ligands
US8114964B2 (en) * 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
US20070155014A1 (en) * 2005-07-20 2007-07-05 Invitrogen Corporation Methods for increasing efficiency of homologous recombination
US20080305519A1 (en) * 2006-02-23 2008-12-11 Qing Lin Biochemical method for specific protein labeling
WO2007139895A2 (en) * 2006-05-24 2007-12-06 Cellumen, Inc. Method for modeling a disease
EP2205752B1 (en) * 2007-10-25 2016-08-10 Sangamo BioSciences, Inc. Methods and compositions for targeted integration
CA2720903C (en) * 2008-04-14 2019-01-15 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
SG191561A1 (en) * 2008-08-22 2013-07-31 Sangamo Biosciences Inc Methods and compositions for targeted single-stranded cleavage and targeted integration

Also Published As

Publication number Publication date
US20180134759A1 (en) 2018-05-17
ES2565216T3 (es) 2016-04-01
JP2013523181A (ja) 2013-06-17
CN107805278A (zh) 2018-03-16
CN102959078B (zh) 2016-01-20
CA2795643C (en) 2018-07-17
EP2558575A1 (en) 2013-02-20
US20130059362A1 (en) 2013-03-07
BR112012026379A2 (pt) 2015-09-22
US20180105564A1 (en) 2018-04-19
CN102971421A (zh) 2013-03-13
EP2558575A4 (en) 2013-10-30
EP2558574A1 (en) 2013-02-20
CA2795643A1 (en) 2011-10-20
JP5841996B2 (ja) 2016-01-13
US20130065310A1 (en) 2013-03-14
US20130059388A1 (en) 2013-03-07
CA2795636C (en) 2018-07-31
JP5841997B2 (ja) 2016-01-13
WO2011130346A1 (en) 2011-10-20
JP2013523180A (ja) 2013-06-17
EP2558575B1 (en) 2015-12-16
EP2558574B1 (en) 2015-03-18
WO2011130345A1 (en) 2011-10-20
CA2795636A1 (en) 2011-10-20
DK2558575T3 (en) 2016-03-21
CN102959078A (zh) 2013-03-06
KR20130055588A (ko) 2013-05-28
WO2011130343A1 (en) 2011-10-20
EP2558574A4 (en) 2013-10-30

Similar Documents

Publication Publication Date Title
DK2558575T3 (en) METHODS FOR GENERATION OF endogenous MARK PROTEIN.
US8771985B2 (en) Genome editing of a Rosa locus using zinc-finger nucleases
US9512444B2 (en) Genome editing using targeting endonucleases and single-stranded nucleic acids
US20160145645A1 (en) Targeted integration
US20110023153A1 (en) Genomic editing of genes involved in alzheimer's disease
US20120030778A1 (en) Genomic editing of genes involved with parkinsons disease
US20120159654A1 (en) Genome editing of genes involved in adme and toxicology in animals
US20110023141A1 (en) Genomic editing of genes involved with parkinson's disease
US20120023599A1 (en) Genome editing of cytochrome p450 in animals
KR20110101175A (ko) 징크 핑거 뉴클레아제를 이용한 랫트의 유전체 편집

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20121105

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160411

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170914

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20180718

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20181023

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180718

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20170914

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I